| Name | Title | Contact Details |
|---|
Milestone Scientific Inc. (MLSS) is a biomedical technology research and development company that patents, designs and develops innovative diagnostic and therapeutic injection technologies and instruments for medical, dental, cosmetic and veterinary applications. Milestone`s computer-controlled systems are designed to make injections precise, efficient, and virtually painless. Milestone`s proprietary DPS Dynamic Pressure Sensing technology® is our technology platform that advances the development of next-generation devices, regulating flow rate and monitoring pressure from the tip of the needle, through platform extensions for local anesthesia for subcutaneous drug delivery, with specific applications for cosmetic botulinum toxin injections, epidural space identification in regional anesthesia procedures and intra-articular joint injections.
Acutus Medical is committed to pioneering a breakthrough technology to optimize the treatment strategies for complex cardiac arrhythmias by developing innovative, safe, efficacious, and cost-effective solutions for individuals suffering from these complex cardiac arrhythmias. Our mission is to develop and market a platform technology of safe, cost-effective and clinically advanced tools for the minimally invasive diagnosis (mapping) of complex arrhythmias (Atrial Fibrillation and Ventricular Tachycardia) that enable Physicians to optimize treatments and expand the ablation/therapeutic markets. In the pursuit of our mission, we will conduct all of our activities with the highest integrity and strive to become the world’s most valued company within the markets we serve to patients, customers, colleagues, investors, business partners, employees, and the communities in which we work and live.
GIW is a clinical stage company creating a new category in healthcare designed to create less invasive surgery & reduce healthcare costs
West Side Resources is a Irvine, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
MediBeacon was formed in 2012 specifically to acquire the optical diagnostic program from Mallinckrodt, the Pharmaceuticals business of Covidien. MediBeacon mission is to commercialize biocompatible optical diagnostic agents for physiological monitoring, surgical guidance, and imaging of pathological disease in the human population. Several product concepts in these arenas are contained in the MediBeacon Intellectual Property (IP) portfolio.